Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 non-inferiority trial of Noyan Pajouhan HPV 16/18 vaccine versus Cervarix in healthy young women
IRCT20090526001952N9Phase 3Completed
- Sponsor
- Noyan Pajouhan Biopharma
- Start
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by Noyan Pajouhan Biopharma. Primary endpoint: Antibody titer against human papillomavirus types 16 and 18. Started Jul 2019; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on IRCT20090526001952N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090526001952N9.